FDA's Risk Communications On Public Health Threats To Be Tested
Agency-sponsored focus groups will assess information about medical countermeasures; project builds on previous FDA efforts to understand consumer perceptions of risk communications.
You may also be interested in...
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.